Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014:2014:158251.
doi: 10.1155/2014/158251. Epub 2014 Jul 17.

Diabetic retinopathy treated with laser photocoagulation and the indirect effect on glycaemic control

Anna Praidou  1 , Sofia Androudi  2 , Periklis Brazitikos  2 , George Karakiulakis  3 , Eleni Papakonstantinou  3 , Ioannis Tsinopoulos  2 , Stavros Dimitrakos  2
Affiliations

Diabetic retinopathy treated with laser photocoagulation and the indirect effect on glycaemic control

Anna Praidou et al. J Diabetes Res. 2014.

Abstract

Purpose: To identify any possible relation between glycaemic control and previous laser photocoagulation for diabetic retinopathy.

Methods: Seventy-two patients with diabetes were included in the study and were separated into 2 groups according to previous treatment (group A) or not (group B) with argon laser photocoagulation. Glycaemic control was estimated by measuring blood levels of HbA1c in four consecutive measurements.

Results: Blood levels of HbA1c in group A were significantly lower 3, 6, and 12 months after laser treatment as compared to blood levels of HbA1c before laser treatment (7.1 ± 0.4% versus 7.6 ± 0.9%, 7.2 ± 0.2% versus 7.6 ± 0.9%, and 7.1 ± 0.2% versus 7.6 ± 0.9%, resp., all P < 0.05). Blood levels of HbA1c in group B did not differ significantly in four consecutive measurements.

Conclusion: Our results suggest that we should anticipate a better glycaemic control in cases of patients with diabetes previously treated with laser photocoagulation.

PubMed Disclaimer

References

    1. Fong DS, Aiello LP, Ferris FL, III, Klein R. Diabetic retinopathy. Diabetes Care. 2004;27(10):2540–2553. - PubMed
    1. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. The Journal of the American Medical Association. 2007;298(8):902–916. - PubMed
    1. Praidou A, Papakonstantinou E, Androudi S, Georgiadis N, Karakiulakis G, Dimitrakos S. Vitreous and serum levels of vascular endothelial growth factor and platelet-derived growth factor and their correlation in patients with non-proliferative diabetic retinopathy and clinically significant macula oedema. Acta Ophthalmologica. 2011;89(3):248–254. - PubMed
    1. Praidou A, Androudi S, Brazitikos P, Karakiulakis G, Papakonstantinou E, Dimitrakos S. Angiogenic growth factors and their inhibitors in diabetic retinopathy. Current Diabetes Reviews. 2010;6(5):304–312. - PubMed
    1. Praidou A, Klangas I, Papakonstantinou E, et al. Vitreous and serum levels of platelet-derived growth factor and their correlation in patients with proliferative diabetic retinopathy. Current Eye Research. 2009;34(2):152–161. - PubMed

LinkOut - more resources